Eli Lilly's Q2 earnings beat expectations, fueled by strong sales of diabetes and obesity drugs, leading to a raised 2025 profit forecast.

Eli Lilly and Company reported strong second-quarter earnings, with $6.31 in adjusted EPS, surpassing estimates by $0.72, and $15.56 billion in revenue, a 37.6% year-over-year increase, driven by demand for diabetes and obesity treatments like Mounjaro and Zepbound. The company raised its 2025 full-year EPS guidance to $21.75–$23.00, with analysts forecasting $23.48. Trading at $724.73, the stock has a market cap of $685.93 billion, a P/E ratio of 47.37, and a consensus "Moderate Buy" rating with a target price of $939.61. Insiders collectively purchased 4,514 shares worth nearly $2.9 million in the quarter, while several institutional investors adjusted their stakes. The company maintains strong financials, including a 92.72% return on equity and 25.91% net margin.